NCT00326157View on ClinicalTrials.gov

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

November 30, 2009

Conditions

Fungus Diseases

Interventions

DRUG

AmBisome

3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration

Trial Locations (1)

20146

Gilead Sciences, Milan